Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$463.15 USD

463.15
947,949

+1.39 (0.30%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $463.00 -0.15 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod

Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.

    Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX

    The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.

      Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)

      Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

        Is Celgene (CELG) Poised for a Beat This Earnings Season?

        Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.

          Is Gilead (GILD) Poised for a Beat This Earnings Season?

          A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.

            Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?

            Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.

              Tirthankar Chakraborty headshot

              4 of the Most Efficient Stocks to Buy Now

              Companies with favorable efficiency levels are likely to be on investors' radar irrespective of market conditions.

                Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

                Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

                  What's in the Cards for Novartis (NVS) This Earnings Season?

                  Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.

                    Arpita Dutt headshot

                    Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

                    Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.

                      Will Quest Diagnostics (DGX) Disappoint in Q3 Earnings?

                      The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.

                        Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day

                        Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day

                          Kevin Cook headshot

                          Bull of the Day: Vertex Pharmaceuticals (VRTX)

                          Cystic fibrosis is a life-shortening genetic disorder affecting 75,000 youth and Vertex is leading treatment with multiple breakthroughs

                            Is a Beat in Store for Abbott (ABT) This Earnings Season?

                            Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.

                              Arpita Dutt headshot

                              Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

                              With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

                                Amgen Label Expansion Application for Prolia Accepted by FDA

                                Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).

                                  Why the Earnings Streak Will Continue for Vertex Pharmaceuticals (VRTX)

                                  Vertex Pharmaceuticals (VRTX) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.

                                    Arpita Dutt headshot

                                    Forget Teva (TEVA), Buy These 5 Drug Stocks Instead

                                    With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation

                                      Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.

                                        3 Top-Ranked Big Biotech Stocks to Buy Now

                                        With biotech stocks on a tear, here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one's portfolio

                                          Mallinckrodt (MNK) Closes InfaCare Pharmaceutical Buyout

                                          Mallinckrodt (MNK) acquires privately-held InfaCare Pharmaceutical Corporation to diversify portfolio.

                                            Mark Vickery headshot

                                            Top Stock Reports for Goldman Sachs, PepsiCo and Johnson & Johnson

                                            Today's Research Daily features new research reports on 12 major stocks, including Goldman Sachs Group Inc (GS), PepsiCo, Inc. (PEP) and Johnson & Johnson (JNJ)

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues

                                              Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

                                                Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

                                                  The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard

                                                  The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard